產(chǎn)品參數(shù)
|
品 名
|
貨 號
|
CAS 號
|
純 度
|
規(guī) 格
|
價格
|
|
Natalizumab
|
PHM220228
|
189261-10-7
|
≥99.10%
|
10 mg
|
￥8250
|
|
25 mg
|
￥12500
|
產(chǎn)品簡介
Natalizumab 是一種重組的人源化單克隆抗體，
與 α4β1-整聯(lián)蛋白 (α4β1-integrin) 結(jié)合并阻斷其與血管細(xì)胞粘附分子 1 (VCAM-1) 的相互作用。
Natalizumab 可用于復(fù)發(fā)緩解型多發(fā)性硬化癥和克羅恩氏病的研究。
Natalizumab 也可阻止 linba 細(xì)胞進(jìn)入 zhongshu 神經(jīng)系統(tǒng)，從而防止急性脫髓鞘復(fù)發(fā)。
詳細(xì)介紹
|
生物活性
|
Natalizumab is a recombinant, humanized monoclonal antibody, binds to α4β1-integrin
and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab
can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
Natalizumab is also the first targeted therapy which blocks an essential mechanism for
lymphocyte entry to the CNS and thus prevents acute demyelinating relapses.
|
|
體外研究
(In Vitro)
|
Natalizumab, a recombinant, humanized antibody, binds to α4β1-integrin and blocks its
interaction with VCAM-1. As a result, leukocyte migration into brain tissue is inhibited,
reducing inflammation and preventing the formation of lesions. Natalizumab may also
inhibit ongoing central nervous system (CNS) inflammation, mediated by leukocytes
already present in the CNS, by interrupting the interactions between α4-integrin-expressing
leukocytes and extracellular matrix proteins such as fibronectin and osteopontin.
MCE has not independently confirmed the accuracy of these methods.
They are for reference only.
|
|
體內(nèi)研究
(In Vivo)
|
Natalizumab binds rapidly and with high affinity to α4-integrin. Maximal binding (≥80%
saturation), measured in vitro on isolated lymphocyte membranes, occurred 24 hours
after intravenous (IV) doses of natalizumab 1 mg/kg to 6 mg/kg.
MCE has not independently confirmed the accuracy of these methods.
They are for reference only.
|
|
CAS 號
|
189261-10-7
|
|
中文名稱
|
那他珠單抗
|
|
儲存方式
|
Please store the product under the recommended conditions in the Certificate of Analysis.
|
